Study of Navlimetostat for advanced solid tumors with specific gene change
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has a specific gene change (MTAP deletion or loss) confirmed by a special test.
- Your cancer must be advanced (cannot be removed by surgery or has spread) and standard treatments no longer work.
- You must be in good physical condition (ECOG score 0 or 1), meaning you can care for yourself and are up and about more than 50% of the day.
- You must have at least one tumor that can be measured on a scan (CT or MRI).
- You must not have had prior treatment with a drug that targets PRMT5 or MAT2A (related to MTAP).
- You must not have active brain tumors that have spread to the brain or certain severe stomach/intestinal problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
This trial tests an investigational drug called HSK41959 combined with standard cancer therapy for people whose tumors have a specific genetic change (MTAP deletion). The goal is to see if the combination is safe and works better against advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.